CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): Analysis from two phase 2 studies

Ayed O. Ayed, Annalisa Chiappella, Levi Pederson, Betsy R. Laplant, Angela Giovanna Congiu, Gianluca Gaidano, Michele Spina, Alessandro Re, Federica Cavallo, Gerardo Musuraca, William R. MacOn, Thomas Witzig, Umberto Vitolo, Grzegorz S. Nowakowski

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a devastating event occurring in ~ 5% of patients treated with R-CHOP. We hypothesized that adding lenalidomide to R-CHOP (R2CHOP) may decrease the risk of CNS relapse. We analyzed records for patients with DLBCL from two R2CHOP trials. We assessed variables pertinent to the CNS-International Prognostic Index (CNS-IPI) scoring system and classified patients into groups of low, intermediate, and high risk of CNS relapse. The 2-year CNS relapse rate for each risk group was estimated using the Kaplan-Meier method and compared with reported rates in cohorts treated with contemporary chemoimmunotherapy. A total of 136 patients were included. Mean age was 65 and median follow-up was 48.2 months. 10.3, 71.3, and 18.4% of patients were classified into low, intermediate, and high-risk CNS-IPI groups, respectively. Only one of 136 patients developed CNS relapse, corresponding to an incidence of 0.7% and an estimated 2-year CNS relapse rate of 0.9% for the entire R2CHOP cohort. The estimated 2-year CNS relapse rates for the low, intermediate, and high-risk groups were 0, 0, and 5.0%, respectively. Frontline therapy with R2CHOP in patients with DLBCL is associated with a lower-than-expected rate of CNS relapse.

Original languageEnglish (US)
Article number63
JournalBlood cancer journal
Issue number7
StatePublished - Jul 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): Analysis from two phase 2 studies'. Together they form a unique fingerprint.

Cite this